{"title":"普拉克索增强治疗难治性抑郁症有效","authors":"","doi":"10.1002/pu.31355","DOIUrl":null,"url":null,"abstract":"<p>Augmenting antidepressant treatment with the dopamine D2/D3 receptor agonist pramipexole led to improvement in depressive symptoms relative to placebo at 12 weeks in patients with treatment-resistant depression, a randomized trial has found. Treatment discontinuation due to adverse events was more prevalent in the pramipexole group, investigators reported. Study results were published online June 29, 2025, in <i>Lancet Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 10","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Augmentation with pramipexole efficacious for treatment-resistant depression\",\"authors\":\"\",\"doi\":\"10.1002/pu.31355\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Augmenting antidepressant treatment with the dopamine D2/D3 receptor agonist pramipexole led to improvement in depressive symptoms relative to placebo at 12 weeks in patients with treatment-resistant depression, a randomized trial has found. Treatment discontinuation due to adverse events was more prevalent in the pramipexole group, investigators reported. Study results were published online June 29, 2025, in <i>Lancet Psychiatry</i>.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 10\",\"pages\":\"1-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31355\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Augmentation with pramipexole efficacious for treatment-resistant depression
Augmenting antidepressant treatment with the dopamine D2/D3 receptor agonist pramipexole led to improvement in depressive symptoms relative to placebo at 12 weeks in patients with treatment-resistant depression, a randomized trial has found. Treatment discontinuation due to adverse events was more prevalent in the pramipexole group, investigators reported. Study results were published online June 29, 2025, in Lancet Psychiatry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
